Upregulated Expression of C-X-C Chemokine Receptor 4 Is an Independent Prognostic Predictor for Patients with Gastric Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  He, Hongyong ^a   Wang, Cong ^a   Shen, Zhenbin ^a   Fang, Yong ^a   Wang, Xuefei ^a   Chen, Weidong ^a   Liu, Fenglin ^a   Qin, Xinyu ^a   Sun, Yihong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN LOCALIZATION; RECEPTOR DENSITY; RECEPTOR UPREGULATION; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMACH CANCER; TISSUE DISTRIBUTION;

FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CXCR4; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84881188351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071864     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ, (2009) Gastric cancer. Lancet 374: 477-490. doi:10.1016/S0140-6736(09)60617-6. PubMed: 19625077.
3. Yang L, (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20. PubMed: 16440411.
4. Lim L, Michael M, Mann GB, Leong T, (2005) Adjuvant therapy in gastric cancer. J Clin Oncol 23: 6220-6232. doi:10.1200/JCO.2005.11.593. PubMed: 16135489.
5. Stock M, Otto F, (2005) Gene deregulation in gastric cancer. Gene 360: 1-19. doi:10.1016/j.gene.2005.06.026. PubMed: 16154715.
6. He H, Chen W, Wang X, Wang C, Liu F, et al. (2012) Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. Cancer Sci 103: 1296-1303. doi:10.1111/j.1349-7006.2012.02295.x. PubMed: 22471696.
7. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, et al. (2005) Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8: 86-94. doi:10.1007/s10120-005-0320-0. PubMed: 15864715.
8. Vandercappellen J, Van Damme J, Struyf S, (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267: 226-244. doi:10.1016/j.canlet.2008.04.050. PubMed: 18579287.
9. Iwasa S, Yanagawa T, Fan J, Katoh R, (2009) Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res 29: 4751-4758. PubMed: 20032431.
10. Teicher BA, Fricker,. (2010) SP CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931. doi:10.1158/1078-0432.CCR-09-2329. PubMed: 20484021.
11. Ishigami S, Natsugoe S, Okumura H, Matsumoto M, Nakajo A, et al. (2007) Clinical implication of CXCL12 expression in gastric cancer. Ann Surg Oncol 14: 3154-3158. doi:10.1245/s10434-007-9521-6. PubMed: 17653799.
12. Ahn JY, Seo K, Weinberg OK, Arber DA, (2013) The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol 21: 79-84. PubMed: 22914607.
13. Parker CC, Kim RH, Li BD, Chu QD, (2012) The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients. J Surg Oncol 106: 393-398. doi:10.1002/jso.23113. PubMed: 22473623.
14. Jung SJ, Kim CI, Park CH, Chang HS, Kim BH, et al. (2011) Correlation between Chemokine Receptor CXCR4 Expression and Prognostic Factors in Patients with Prostate Cancer. Korean J Urol 52: 607-611. doi:10.4111/kju.2011.52.9.607. PubMed: 22025955.
15. Wang X, He H, Zhang H, Chen W, Ji Y, et al. (2013) Clinical and prognostic implications of beta1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer. Cancer Sci 104: 185-193. doi:10.1111/cas.12049. PubMed: 23107376.
16. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, et al. (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26: 2707-2716. doi:10.1200/JCO.2007.15.6521. PubMed: 18509183.
17. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, et al. (2008) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148. doi:10.1016/S1470-2045(08)70004-4. PubMed: 18207460.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072. doi:10.1200/JCO.2004.01.0454. PubMed: 16172462.
19. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, et al. (2009) Gastric cancer. Crit Rev Oncol/Hematol 71: 127-164. doi:10.1016/j.critrevonc.2009.01.004.
20. Kasaian K, Jones SJ, (2011) A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncol 7: 873-894. doi:10.2217/fon.11.63. PubMed: 21732758.
21. Balkwill F, (2003) Chemokine biology in cancer. Semin Immunol 15: 49-55. doi:10.1016/S1044-5323(02)00127-6. PubMed: 12495640.
22. Burger JA, Kipps TJ, (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767. doi:10.1182/blood-2005-08-3182. PubMed: 16269611.
23. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, et al. (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909. doi:10.1200/JCO.2005.05.0245. PubMed: 16782930.
24. Demolin G, Focan C, Plomteux O, Kreutz F, Moeneclaey N, et al. (2008) [Chemotherapy for human gastric cancer: a review]. Rev Med Liege 63: 532-541. PubMed: 19051508.
25. Xie L, Wei J, Qian X, Chen G, Yu L, et al. (2010) CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer. Anticancer Res 30: 2209-2216. PubMed: 20651371.
26. Ying J, Xu Q, Zhang G, Liu B, Zhu L, (2011) The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med Oncol 29: 1716-1722. PubMed: 21630055.
27. Kwak MK, Hur K, Park DJ, Lee HJ, Lee HS, et al. (2005) Expression of chemokine receptors in human gastric cancer. Tumour Biol 26: 65-70. doi:10.1159/000085587. PubMed: 15867478.
28. Sun X, Cheng G, Hao M, Zheng J, Zhou X, et al. (2010) CXCL12/ CXCR4/ CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29: 709-722. doi:10.1007/s10555-010-9256-x. PubMed: 20839032.
29. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, et al. (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17: 2074-2080. doi:10.1158/1078-0432.CCR-10-2636. PubMed: 21349998.
30. De Clercq E, (2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2: 581-587. doi:10.1038/nrd1134. PubMed: 12815382.
31. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113: 4341-4351. doi:10.1182/blood-2008-10-186668. PubMed: 19139079.
32. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, et al. (2006) Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 66: 2181-2187. doi:10.1158/0008-5472.CAN-05-3393. PubMed: 16489019.